Showing results (21-30 of 108) with videos related to
Sort By:
Pageof 11
Therapeutic Advances in Medical Oncology|June 30, 2023
Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancerRui Wan, Yanrong Guo, Xuezhi Hao, et al.Oncology Reports|September 24, 2015
miR-130a regulates macrophage polarization and is associated with non-small cell lung cancerLin Lin, Haibo Lin, Lin Wang, et al.Journal of Cancer|October 9, 2020
Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimenXuezhi Hao, Yixiang Zhu, Yuxin Mu, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 21, 2016
[Clinicopathologic Characteristics of the Patients in the Elderly Lung Carcinoma]Jie Chen, Xuezhi Hao, Fang Cheng, et al.Thoracic Cancer|July 16, 2021
Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC)Ziyi Xu, Teng Li, Xingsheng Hu, et al.Oncotarget|November 21, 2017
The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in ChinaPuyuan Xing, Yixiang Zhu, Ling Shan, et al.BMC Cancer|March 4, 2023
Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapyZiyi Xu, Xuezhi Hao, Qi Wang, et al.Thoracic Cancer|May 17, 2019
Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutationsShouzheng Wang, Puyuan Xing, Ke Yang, et al.Thoracic Cancer|July 27, 2017
Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysisDi Ma, Jing Wang, Xuezhi Hao, et al.Journal of Hematology & Oncology|January 16, 2019
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumorsYongkun Sun, Lin Yang, Xuezhi Hao, et al.Pageof 11